Inherited Breast Cancer in Nigerian Women
Among Nigerian women, breast cancer is diagnosed at later stages, is more frequently triple-negative disease, and is far more frequently fatal than in Europe or the United States. We evaluated the contribution of an inherited predisposition to breast cancer in this population. Cases were 1,136 women...
Saved in:
Published in | Journal of clinical oncology Vol. 36; no. 28; pp. 2820 - 2825 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
American Society of Clinical Oncology
01.10.2018
|
Subjects | |
Online Access | Get full text |
ISSN | 0732-183X 1527-7755 1527-7755 |
DOI | 10.1200/JCO.2018.78.3977 |
Cover
Abstract | Among Nigerian women, breast cancer is diagnosed at later stages, is more frequently triple-negative disease, and is far more frequently fatal than in Europe or the United States. We evaluated the contribution of an inherited predisposition to breast cancer in this population.
Cases were 1,136 women with invasive breast cancer (mean age at diagnosis, 47.5 ± 11.5 years) ascertained in Ibadan, Nigeria. Patients were selected regardless of age at diagnosis, family history, or prior genetic testing. Controls were 997 women without cancer (mean age at interview, 47.0 ± 12.4 years) from the same communities. BROCA panel sequencing was used to identify loss-of-function mutations in known and candidate breast cancer genes.
Of 577 patients with information on tumor stage, 86.1% (497) were diagnosed at stage III (241) or IV (256). Of 290 patients with information on tumor hormone receptor status and human epidermal growth factor receptor 2, 45.9% (133) had triple-negative breast cancer. Among all cases, 14.7% (167 of 1,136) carried a loss-of-function mutation in a breast cancer gene: 7.0% in BRCA1, 4.1% in BRCA2, 1.0% in PALB2, 0.4% in TP53, and 2.1% in any of 10 other genes. Odds ratios were 23.4 (95% CI, 7.4 to 73.9) for BRCA1 and 10.3 (95% CI, 3.7 to 28.5) for BRCA2. Risks were also significantly associated with PALB2 (11 cases, zero controls; P = .002) and TP53 (five cases, zero controls; P = .036). Compared with other patients, BRCA1 mutation carriers were younger ( P < .001) and more likely to have triple-negative breast cancer ( P = .028).
Among Nigerian women, one in eight cases of invasive breast cancer is a result of inherited mutations in BRCA1, BRCA2, PALB2, or TP53, and breast cancer risks associated with these genes are extremely high. Given limited resources, prevention and early detection services should be especially focused on these highest-risk women. |
---|---|
AbstractList | Among Nigerian women, breast cancer is diagnosed at later stages, is more frequently triple-negative disease, and is far more frequently fatal than in Europe or the United States. We evaluated the contribution of an inherited predisposition to breast cancer in this population.PURPOSEAmong Nigerian women, breast cancer is diagnosed at later stages, is more frequently triple-negative disease, and is far more frequently fatal than in Europe or the United States. We evaluated the contribution of an inherited predisposition to breast cancer in this population.Cases were 1,136 women with invasive breast cancer (mean age at diagnosis, 47.5 ± 11.5 years) ascertained in Ibadan, Nigeria. Patients were selected regardless of age at diagnosis, family history, or prior genetic testing. Controls were 997 women without cancer (mean age at interview, 47.0 ± 12.4 years) from the same communities. BROCA panel sequencing was used to identify loss-of-function mutations in known and candidate breast cancer genes.PATIENTS AND METHODSCases were 1,136 women with invasive breast cancer (mean age at diagnosis, 47.5 ± 11.5 years) ascertained in Ibadan, Nigeria. Patients were selected regardless of age at diagnosis, family history, or prior genetic testing. Controls were 997 women without cancer (mean age at interview, 47.0 ± 12.4 years) from the same communities. BROCA panel sequencing was used to identify loss-of-function mutations in known and candidate breast cancer genes.Of 577 patients with information on tumor stage, 86.1% (497) were diagnosed at stage III (241) or IV (256). Of 290 patients with information on tumor hormone receptor status and human epidermal growth factor receptor 2, 45.9% (133) had triple-negative breast cancer. Among all cases, 14.7% (167 of 1,136) carried a loss-of-function mutation in a breast cancer gene: 7.0% in BRCA1, 4.1% in BRCA2, 1.0% in PALB2, 0.4% in TP53, and 2.1% in any of 10 other genes. Odds ratios were 23.4 (95% CI, 7.4 to 73.9) for BRCA1 and 10.3 (95% CI, 3.7 to 28.5) for BRCA2. Risks were also significantly associated with PALB2 (11 cases, zero controls; P = .002) and TP53 (five cases, zero controls; P = .036). Compared with other patients, BRCA1 mutation carriers were younger ( P < .001) and more likely to have triple-negative breast cancer ( P = .028).RESULTSOf 577 patients with information on tumor stage, 86.1% (497) were diagnosed at stage III (241) or IV (256). Of 290 patients with information on tumor hormone receptor status and human epidermal growth factor receptor 2, 45.9% (133) had triple-negative breast cancer. Among all cases, 14.7% (167 of 1,136) carried a loss-of-function mutation in a breast cancer gene: 7.0% in BRCA1, 4.1% in BRCA2, 1.0% in PALB2, 0.4% in TP53, and 2.1% in any of 10 other genes. Odds ratios were 23.4 (95% CI, 7.4 to 73.9) for BRCA1 and 10.3 (95% CI, 3.7 to 28.5) for BRCA2. Risks were also significantly associated with PALB2 (11 cases, zero controls; P = .002) and TP53 (five cases, zero controls; P = .036). Compared with other patients, BRCA1 mutation carriers were younger ( P < .001) and more likely to have triple-negative breast cancer ( P = .028).Among Nigerian women, one in eight cases of invasive breast cancer is a result of inherited mutations in BRCA1, BRCA2, PALB2, or TP53, and breast cancer risks associated with these genes are extremely high. Given limited resources, prevention and early detection services should be especially focused on these highest-risk women.CONCLUSIONAmong Nigerian women, one in eight cases of invasive breast cancer is a result of inherited mutations in BRCA1, BRCA2, PALB2, or TP53, and breast cancer risks associated with these genes are extremely high. Given limited resources, prevention and early detection services should be especially focused on these highest-risk women. Among Nigerian women, breast cancer is diagnosed at later stages, is more frequently triple-negative disease, and is far more frequently fatal than in Europe or the United States. We evaluated the contribution of an inherited predisposition to breast cancer in this population. Cases were 1,136 women with invasive breast cancer (mean age at diagnosis, 47.5 ± 11.5 years) ascertained in Ibadan, Nigeria. Patients were selected regardless of age at diagnosis, family history, or prior genetic testing. Controls were 997 women without cancer (mean age at interview, 47.0 ± 12.4 years) from the same communities. BROCA panel sequencing was used to identify loss-of-function mutations in known and candidate breast cancer genes. Of 577 patients with information on tumor stage, 86.1% (497) were diagnosed at stage III (241) or IV (256). Of 290 patients with information on tumor hormone receptor status and human epidermal growth factor receptor 2, 45.9% (133) had triple-negative breast cancer. Among all cases, 14.7% (167 of 1,136) carried a loss-of-function mutation in a breast cancer gene: 7.0% in BRCA1, 4.1% in BRCA2, 1.0% in PALB2, 0.4% in TP53, and 2.1% in any of 10 other genes. Odds ratios were 23.4 (95% CI, 7.4 to 73.9) for BRCA1 and 10.3 (95% CI, 3.7 to 28.5) for BRCA2. Risks were also significantly associated with PALB2 (11 cases, zero controls; P = .002) and TP53 (five cases, zero controls; P = .036). Compared with other patients, BRCA1 mutation carriers were younger ( P < .001) and more likely to have triple-negative breast cancer ( P = .028). Among Nigerian women, one in eight cases of invasive breast cancer is a result of inherited mutations in BRCA1, BRCA2, PALB2, or TP53, and breast cancer risks associated with these genes are extremely high. Given limited resources, prevention and early detection services should be especially focused on these highest-risk women. |
Author | Anetor, Imaria Felix, Gabriela E.S. Adeoye, Adewumi Walsh, Tom Odetunde, Abayomi Wang, Shengfeng Lee, Ming K. Yoshimatsu, Toshio F. King, Mary-Claire Babalola, Chinedum P. Olopade, Olufunmilayo I. Gulsuner, Suleyman Zheng, Yonglan Falusi, Adeyinka G. Odedina, Stella Zhang, Jing Casadei, Silvia Ogundiran, Temidayo O. Adebamowo, Clement A. Oluwasola, Abideen O. Ojengbede, Oladosu A. Ademola, Adeyinka Huo, Dezheng |
Author_xml | – sequence: 1 givenname: Yonglan surname: Zheng fullname: Zheng, Yonglan organization: Yonglan Zheng, Shengfeng Wang, Dezheng Huo, Toshio F. Yoshimatsu, Jing Zhang, Gabriela E.S. Felix, and Olufunmilayo I. Olopade, The University of Chicago, Chicago, IL; Tom Walsh, Suleyman Gulsuner, Silvia Casadei, Ming K. Lee, and Mary-Claire King, University of Washington, Seattle, WA; Temidayo O. Ogundiran, Adeyinka Ademola, Adeyinka G. Falusi, Abideen O. Oluwasola, Adewumi Adeoye, Abayomi Odetunde, Chinedum P. Babalola, Oladosu A. Ojengbede, Stella Odedina, Imaria Anetor, University of Ibadan; Clement – sequence: 2 givenname: Tom surname: Walsh fullname: Walsh, Tom organization: Yonglan Zheng, Shengfeng Wang, Dezheng Huo, Toshio F. Yoshimatsu, Jing Zhang, Gabriela E.S. Felix, and Olufunmilayo I. Olopade, The University of Chicago, Chicago, IL; Tom Walsh, Suleyman Gulsuner, Silvia Casadei, Ming K. Lee, and Mary-Claire King, University of Washington, Seattle, WA; Temidayo O. Ogundiran, Adeyinka Ademola, Adeyinka G. Falusi, Abideen O. Oluwasola, Adewumi Adeoye, Abayomi Odetunde, Chinedum P. Babalola, Oladosu A. Ojengbede, Stella Odedina, Imaria Anetor, University of Ibadan; Clement – sequence: 3 givenname: Suleyman surname: Gulsuner fullname: Gulsuner, Suleyman organization: Yonglan Zheng, Shengfeng Wang, Dezheng Huo, Toshio F. Yoshimatsu, Jing Zhang, Gabriela E.S. Felix, and Olufunmilayo I. Olopade, The University of Chicago, Chicago, IL; Tom Walsh, Suleyman Gulsuner, Silvia Casadei, Ming K. Lee, and Mary-Claire King, University of Washington, Seattle, WA; Temidayo O. Ogundiran, Adeyinka Ademola, Adeyinka G. Falusi, Abideen O. Oluwasola, Adewumi Adeoye, Abayomi Odetunde, Chinedum P. Babalola, Oladosu A. Ojengbede, Stella Odedina, Imaria Anetor, University of Ibadan; Clement – sequence: 4 givenname: Silvia surname: Casadei fullname: Casadei, Silvia organization: Yonglan Zheng, Shengfeng Wang, Dezheng Huo, Toshio F. Yoshimatsu, Jing Zhang, Gabriela E.S. Felix, and Olufunmilayo I. Olopade, The University of Chicago, Chicago, IL; Tom Walsh, Suleyman Gulsuner, Silvia Casadei, Ming K. Lee, and Mary-Claire King, University of Washington, Seattle, WA; Temidayo O. Ogundiran, Adeyinka Ademola, Adeyinka G. Falusi, Abideen O. Oluwasola, Adewumi Adeoye, Abayomi Odetunde, Chinedum P. Babalola, Oladosu A. Ojengbede, Stella Odedina, Imaria Anetor, University of Ibadan; Clement – sequence: 5 givenname: Ming K. surname: Lee fullname: Lee, Ming K. organization: Yonglan Zheng, Shengfeng Wang, Dezheng Huo, Toshio F. Yoshimatsu, Jing Zhang, Gabriela E.S. Felix, and Olufunmilayo I. Olopade, The University of Chicago, Chicago, IL; Tom Walsh, Suleyman Gulsuner, Silvia Casadei, Ming K. Lee, and Mary-Claire King, University of Washington, Seattle, WA; Temidayo O. Ogundiran, Adeyinka Ademola, Adeyinka G. Falusi, Abideen O. Oluwasola, Adewumi Adeoye, Abayomi Odetunde, Chinedum P. Babalola, Oladosu A. Ojengbede, Stella Odedina, Imaria Anetor, University of Ibadan; Clement – sequence: 6 givenname: Temidayo O. surname: Ogundiran fullname: Ogundiran, Temidayo O. organization: Yonglan Zheng, Shengfeng Wang, Dezheng Huo, Toshio F. Yoshimatsu, Jing Zhang, Gabriela E.S. Felix, and Olufunmilayo I. Olopade, The University of Chicago, Chicago, IL; Tom Walsh, Suleyman Gulsuner, Silvia Casadei, Ming K. Lee, and Mary-Claire King, University of Washington, Seattle, WA; Temidayo O. Ogundiran, Adeyinka Ademola, Adeyinka G. Falusi, Abideen O. Oluwasola, Adewumi Adeoye, Abayomi Odetunde, Chinedum P. Babalola, Oladosu A. Ojengbede, Stella Odedina, Imaria Anetor, University of Ibadan; Clement – sequence: 7 givenname: Adeyinka surname: Ademola fullname: Ademola, Adeyinka organization: Yonglan Zheng, Shengfeng Wang, Dezheng Huo, Toshio F. Yoshimatsu, Jing Zhang, Gabriela E.S. Felix, and Olufunmilayo I. Olopade, The University of Chicago, Chicago, IL; Tom Walsh, Suleyman Gulsuner, Silvia Casadei, Ming K. Lee, and Mary-Claire King, University of Washington, Seattle, WA; Temidayo O. Ogundiran, Adeyinka Ademola, Adeyinka G. Falusi, Abideen O. Oluwasola, Adewumi Adeoye, Abayomi Odetunde, Chinedum P. Babalola, Oladosu A. Ojengbede, Stella Odedina, Imaria Anetor, University of Ibadan; Clement – sequence: 8 givenname: Adeyinka G. surname: Falusi fullname: Falusi, Adeyinka G. organization: Yonglan Zheng, Shengfeng Wang, Dezheng Huo, Toshio F. Yoshimatsu, Jing Zhang, Gabriela E.S. Felix, and Olufunmilayo I. Olopade, The University of Chicago, Chicago, IL; Tom Walsh, Suleyman Gulsuner, Silvia Casadei, Ming K. Lee, and Mary-Claire King, University of Washington, Seattle, WA; Temidayo O. Ogundiran, Adeyinka Ademola, Adeyinka G. Falusi, Abideen O. Oluwasola, Adewumi Adeoye, Abayomi Odetunde, Chinedum P. Babalola, Oladosu A. Ojengbede, Stella Odedina, Imaria Anetor, University of Ibadan; Clement – sequence: 9 givenname: Clement A. surname: Adebamowo fullname: Adebamowo, Clement A. organization: Yonglan Zheng, Shengfeng Wang, Dezheng Huo, Toshio F. Yoshimatsu, Jing Zhang, Gabriela E.S. Felix, and Olufunmilayo I. Olopade, The University of Chicago, Chicago, IL; Tom Walsh, Suleyman Gulsuner, Silvia Casadei, Ming K. Lee, and Mary-Claire King, University of Washington, Seattle, WA; Temidayo O. Ogundiran, Adeyinka Ademola, Adeyinka G. Falusi, Abideen O. Oluwasola, Adewumi Adeoye, Abayomi Odetunde, Chinedum P. Babalola, Oladosu A. Ojengbede, Stella Odedina, Imaria Anetor, University of Ibadan; Clement – sequence: 10 givenname: Abideen O. surname: Oluwasola fullname: Oluwasola, Abideen O. organization: Yonglan Zheng, Shengfeng Wang, Dezheng Huo, Toshio F. Yoshimatsu, Jing Zhang, Gabriela E.S. Felix, and Olufunmilayo I. Olopade, The University of Chicago, Chicago, IL; Tom Walsh, Suleyman Gulsuner, Silvia Casadei, Ming K. Lee, and Mary-Claire King, University of Washington, Seattle, WA; Temidayo O. Ogundiran, Adeyinka Ademola, Adeyinka G. Falusi, Abideen O. Oluwasola, Adewumi Adeoye, Abayomi Odetunde, Chinedum P. Babalola, Oladosu A. Ojengbede, Stella Odedina, Imaria Anetor, University of Ibadan; Clement – sequence: 11 givenname: Adewumi surname: Adeoye fullname: Adeoye, Adewumi organization: Yonglan Zheng, Shengfeng Wang, Dezheng Huo, Toshio F. Yoshimatsu, Jing Zhang, Gabriela E.S. Felix, and Olufunmilayo I. Olopade, The University of Chicago, Chicago, IL; Tom Walsh, Suleyman Gulsuner, Silvia Casadei, Ming K. Lee, and Mary-Claire King, University of Washington, Seattle, WA; Temidayo O. Ogundiran, Adeyinka Ademola, Adeyinka G. Falusi, Abideen O. Oluwasola, Adewumi Adeoye, Abayomi Odetunde, Chinedum P. Babalola, Oladosu A. Ojengbede, Stella Odedina, Imaria Anetor, University of Ibadan; Clement – sequence: 12 givenname: Abayomi surname: Odetunde fullname: Odetunde, Abayomi organization: Yonglan Zheng, Shengfeng Wang, Dezheng Huo, Toshio F. Yoshimatsu, Jing Zhang, Gabriela E.S. Felix, and Olufunmilayo I. Olopade, The University of Chicago, Chicago, IL; Tom Walsh, Suleyman Gulsuner, Silvia Casadei, Ming K. Lee, and Mary-Claire King, University of Washington, Seattle, WA; Temidayo O. Ogundiran, Adeyinka Ademola, Adeyinka G. Falusi, Abideen O. Oluwasola, Adewumi Adeoye, Abayomi Odetunde, Chinedum P. Babalola, Oladosu A. Ojengbede, Stella Odedina, Imaria Anetor, University of Ibadan; Clement – sequence: 13 givenname: Chinedum P. surname: Babalola fullname: Babalola, Chinedum P. organization: Yonglan Zheng, Shengfeng Wang, Dezheng Huo, Toshio F. Yoshimatsu, Jing Zhang, Gabriela E.S. Felix, and Olufunmilayo I. Olopade, The University of Chicago, Chicago, IL; Tom Walsh, Suleyman Gulsuner, Silvia Casadei, Ming K. Lee, and Mary-Claire King, University of Washington, Seattle, WA; Temidayo O. Ogundiran, Adeyinka Ademola, Adeyinka G. Falusi, Abideen O. Oluwasola, Adewumi Adeoye, Abayomi Odetunde, Chinedum P. Babalola, Oladosu A. Ojengbede, Stella Odedina, Imaria Anetor, University of Ibadan; Clement – sequence: 14 givenname: Oladosu A. surname: Ojengbede fullname: Ojengbede, Oladosu A. organization: Yonglan Zheng, Shengfeng Wang, Dezheng Huo, Toshio F. Yoshimatsu, Jing Zhang, Gabriela E.S. Felix, and Olufunmilayo I. Olopade, The University of Chicago, Chicago, IL; Tom Walsh, Suleyman Gulsuner, Silvia Casadei, Ming K. Lee, and Mary-Claire King, University of Washington, Seattle, WA; Temidayo O. Ogundiran, Adeyinka Ademola, Adeyinka G. Falusi, Abideen O. Oluwasola, Adewumi Adeoye, Abayomi Odetunde, Chinedum P. Babalola, Oladosu A. Ojengbede, Stella Odedina, Imaria Anetor, University of Ibadan; Clement – sequence: 15 givenname: Stella surname: Odedina fullname: Odedina, Stella organization: Yonglan Zheng, Shengfeng Wang, Dezheng Huo, Toshio F. Yoshimatsu, Jing Zhang, Gabriela E.S. Felix, and Olufunmilayo I. Olopade, The University of Chicago, Chicago, IL; Tom Walsh, Suleyman Gulsuner, Silvia Casadei, Ming K. Lee, and Mary-Claire King, University of Washington, Seattle, WA; Temidayo O. Ogundiran, Adeyinka Ademola, Adeyinka G. Falusi, Abideen O. Oluwasola, Adewumi Adeoye, Abayomi Odetunde, Chinedum P. Babalola, Oladosu A. Ojengbede, Stella Odedina, Imaria Anetor, University of Ibadan; Clement – sequence: 16 givenname: Imaria surname: Anetor fullname: Anetor, Imaria organization: Yonglan Zheng, Shengfeng Wang, Dezheng Huo, Toshio F. Yoshimatsu, Jing Zhang, Gabriela E.S. Felix, and Olufunmilayo I. Olopade, The University of Chicago, Chicago, IL; Tom Walsh, Suleyman Gulsuner, Silvia Casadei, Ming K. Lee, and Mary-Claire King, University of Washington, Seattle, WA; Temidayo O. Ogundiran, Adeyinka Ademola, Adeyinka G. Falusi, Abideen O. Oluwasola, Adewumi Adeoye, Abayomi Odetunde, Chinedum P. Babalola, Oladosu A. Ojengbede, Stella Odedina, Imaria Anetor, University of Ibadan; Clement – sequence: 17 givenname: Shengfeng surname: Wang fullname: Wang, Shengfeng organization: Yonglan Zheng, Shengfeng Wang, Dezheng Huo, Toshio F. Yoshimatsu, Jing Zhang, Gabriela E.S. Felix, and Olufunmilayo I. Olopade, The University of Chicago, Chicago, IL; Tom Walsh, Suleyman Gulsuner, Silvia Casadei, Ming K. Lee, and Mary-Claire King, University of Washington, Seattle, WA; Temidayo O. Ogundiran, Adeyinka Ademola, Adeyinka G. Falusi, Abideen O. Oluwasola, Adewumi Adeoye, Abayomi Odetunde, Chinedum P. Babalola, Oladosu A. Ojengbede, Stella Odedina, Imaria Anetor, University of Ibadan; Clement – sequence: 18 givenname: Dezheng surname: Huo fullname: Huo, Dezheng organization: Yonglan Zheng, Shengfeng Wang, Dezheng Huo, Toshio F. Yoshimatsu, Jing Zhang, Gabriela E.S. Felix, and Olufunmilayo I. Olopade, The University of Chicago, Chicago, IL; Tom Walsh, Suleyman Gulsuner, Silvia Casadei, Ming K. Lee, and Mary-Claire King, University of Washington, Seattle, WA; Temidayo O. Ogundiran, Adeyinka Ademola, Adeyinka G. Falusi, Abideen O. Oluwasola, Adewumi Adeoye, Abayomi Odetunde, Chinedum P. Babalola, Oladosu A. Ojengbede, Stella Odedina, Imaria Anetor, University of Ibadan; Clement – sequence: 19 givenname: Toshio F. surname: Yoshimatsu fullname: Yoshimatsu, Toshio F. organization: Yonglan Zheng, Shengfeng Wang, Dezheng Huo, Toshio F. Yoshimatsu, Jing Zhang, Gabriela E.S. Felix, and Olufunmilayo I. Olopade, The University of Chicago, Chicago, IL; Tom Walsh, Suleyman Gulsuner, Silvia Casadei, Ming K. Lee, and Mary-Claire King, University of Washington, Seattle, WA; Temidayo O. Ogundiran, Adeyinka Ademola, Adeyinka G. Falusi, Abideen O. Oluwasola, Adewumi Adeoye, Abayomi Odetunde, Chinedum P. Babalola, Oladosu A. Ojengbede, Stella Odedina, Imaria Anetor, University of Ibadan; Clement – sequence: 20 givenname: Jing surname: Zhang fullname: Zhang, Jing organization: Yonglan Zheng, Shengfeng Wang, Dezheng Huo, Toshio F. Yoshimatsu, Jing Zhang, Gabriela E.S. Felix, and Olufunmilayo I. Olopade, The University of Chicago, Chicago, IL; Tom Walsh, Suleyman Gulsuner, Silvia Casadei, Ming K. Lee, and Mary-Claire King, University of Washington, Seattle, WA; Temidayo O. Ogundiran, Adeyinka Ademola, Adeyinka G. Falusi, Abideen O. Oluwasola, Adewumi Adeoye, Abayomi Odetunde, Chinedum P. Babalola, Oladosu A. Ojengbede, Stella Odedina, Imaria Anetor, University of Ibadan; Clement – sequence: 21 givenname: Gabriela E.S. surname: Felix fullname: Felix, Gabriela E.S. organization: Yonglan Zheng, Shengfeng Wang, Dezheng Huo, Toshio F. Yoshimatsu, Jing Zhang, Gabriela E.S. Felix, and Olufunmilayo I. Olopade, The University of Chicago, Chicago, IL; Tom Walsh, Suleyman Gulsuner, Silvia Casadei, Ming K. Lee, and Mary-Claire King, University of Washington, Seattle, WA; Temidayo O. Ogundiran, Adeyinka Ademola, Adeyinka G. Falusi, Abideen O. Oluwasola, Adewumi Adeoye, Abayomi Odetunde, Chinedum P. Babalola, Oladosu A. Ojengbede, Stella Odedina, Imaria Anetor, University of Ibadan; Clement – sequence: 22 givenname: Mary-Claire surname: King fullname: King, Mary-Claire organization: Yonglan Zheng, Shengfeng Wang, Dezheng Huo, Toshio F. Yoshimatsu, Jing Zhang, Gabriela E.S. Felix, and Olufunmilayo I. Olopade, The University of Chicago, Chicago, IL; Tom Walsh, Suleyman Gulsuner, Silvia Casadei, Ming K. Lee, and Mary-Claire King, University of Washington, Seattle, WA; Temidayo O. Ogundiran, Adeyinka Ademola, Adeyinka G. Falusi, Abideen O. Oluwasola, Adewumi Adeoye, Abayomi Odetunde, Chinedum P. Babalola, Oladosu A. Ojengbede, Stella Odedina, Imaria Anetor, University of Ibadan; Clement – sequence: 23 givenname: Olufunmilayo I. surname: Olopade fullname: Olopade, Olufunmilayo I. organization: Yonglan Zheng, Shengfeng Wang, Dezheng Huo, Toshio F. Yoshimatsu, Jing Zhang, Gabriela E.S. Felix, and Olufunmilayo I. Olopade, The University of Chicago, Chicago, IL; Tom Walsh, Suleyman Gulsuner, Silvia Casadei, Ming K. Lee, and Mary-Claire King, University of Washington, Seattle, WA; Temidayo O. Ogundiran, Adeyinka Ademola, Adeyinka G. Falusi, Abideen O. Oluwasola, Adewumi Adeoye, Abayomi Odetunde, Chinedum P. Babalola, Oladosu A. Ojengbede, Stella Odedina, Imaria Anetor, University of Ibadan; Clement |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30130155$$D View this record in MEDLINE/PubMed |
BookMark | eNp1UUtLw0AQXqRiH3r3JDnqIXEfSXZzETT4pNiLordls5m0K-mm7qaC_96E1qKCMDCH-R4z843RwDYWEDomOCIU4_OHfBZRTETERcQyzvfQiCSUh5wnyQCNMGc0JIK9DtHY-zeMSSxYcoCGDJOukmSEzu7tApxpoQyuHCjfBrmyGlxgbPBo5t1I2eClWYI9RPuVqj0cbfsEPd9cP-V34XR2e59fTkMdp7QNlUp4TGglVBbHlDBRQFqoArTCFeVZWeisZKkCztOY6YJCxrAQBVcVKVgpOJugi43ual0sodRgW6dquXJmqdynbJSRvyfWLOS8-ZApSbtbWSdwuhVwzfsafCuXxmuoa2WhWXtJcUYEpSlOOujJT6-dyfd_OgDeALRrvHdQ7SAEyz4C2UUg-wgkF7KPoKOkfyjatKo1Tb-tqf8nfgFuo4nz |
CitedBy_id | crossref_primary_10_1001_jamanetworkopen_2019_15989 crossref_primary_10_1200_JCO_19_00160 crossref_primary_10_1200_GO_20_00587 crossref_primary_10_1093_biomtc_ujae038 crossref_primary_10_1200_GO_20_00541 crossref_primary_10_1038_s41523_020_00214_4 crossref_primary_10_1200_EDBK_319929 crossref_primary_10_1080_14737140_2019_1582335 crossref_primary_10_1002_gcc_23275 crossref_primary_10_1093_jnci_djaa040 crossref_primary_10_1001_jamanetworkopen_2024_38091 crossref_primary_10_1002_jgc4_1374 crossref_primary_10_1007_s12609_020_00364_1 crossref_primary_10_1001_jamanetworkopen_2021_0307 crossref_primary_10_2147_BCTT_S266314 crossref_primary_10_1200_GO_21_00082 crossref_primary_10_3389_fgene_2021_759662 crossref_primary_10_3390_ijms23020628 crossref_primary_10_4103_1596_3519_356811 crossref_primary_10_1038_s41525_024_00446_4 crossref_primary_10_4103_jomt_jomt_33_20 crossref_primary_10_1038_s41576_020_00306_8 crossref_primary_10_1186_s12916_022_02260_0 crossref_primary_10_1002_mgg3_2237 crossref_primary_10_1016_j_gim_2022_03_015 crossref_primary_10_1001_jamanetworkopen_2019_10142 crossref_primary_10_1016_j_jmbbm_2022_105461 crossref_primary_10_4103_atp_atp_36_19 crossref_primary_10_1158_1055_9965_EPI_20_0564 crossref_primary_10_3389_fgene_2023_1302645 crossref_primary_10_1016_j_gde_2020_11_006 crossref_primary_10_1001_jamaoncol_2021_1492 crossref_primary_10_1002_cncr_32049 crossref_primary_10_1002_ijc_33014 crossref_primary_10_1002_gepi_22561 crossref_primary_10_3389_fgene_2021_637887 crossref_primary_10_3389_fonc_2021_732443 crossref_primary_10_1007_s10549_024_07585_3 crossref_primary_10_1158_1055_9965_EPI_22_0869 crossref_primary_10_3389_fgene_2022_834265 crossref_primary_10_1089_gtmb_2022_0160 crossref_primary_10_2147_CMAR_S382903 crossref_primary_10_2217_pgs_2019_0046 crossref_primary_10_1007_s10549_022_06557_9 crossref_primary_10_1158_1078_0432_CCR_23_1526 crossref_primary_10_1615_CritRevOncog_2024051599 crossref_primary_10_1200_EDBK_390522 crossref_primary_10_1002_cam4_2047 crossref_primary_10_1200_JCO_2018_79_3307 crossref_primary_10_1016_j_ejso_2025_109627 crossref_primary_10_1016_j_jtemin_2022_100023 crossref_primary_10_1038_s41467_021_27079_w crossref_primary_10_3390_genes11070798 crossref_primary_10_1016_j_clbc_2020_08_010 crossref_primary_10_3390_healthcare12040462 crossref_primary_10_1093_jnci_djac090 crossref_primary_10_1038_s41598_022_04791_1 crossref_primary_10_1007_s10549_022_06560_0 crossref_primary_10_1002_ijc_34671 crossref_primary_10_1200_GO_21_00140 crossref_primary_10_1200_GO_23_00154 crossref_primary_10_1093_hmg_ddab180 crossref_primary_10_1007_s12253_019_00586_4 crossref_primary_10_1053_j_seminoncol_2023_12_001 crossref_primary_10_11648_j_wjph_20240902_18 crossref_primary_10_1158_1055_9965_EPI_19_0506 crossref_primary_10_1200_OP_21_00236 crossref_primary_10_3389_fonc_2023_1240098 crossref_primary_10_1158_1055_9965_EPI_21_1397 crossref_primary_10_1007_s12553_021_00637_4 crossref_primary_10_1016_j_canep_2020_101739 crossref_primary_10_1126_science_aay4743 crossref_primary_10_1002_sim_10323 crossref_primary_10_2174_1568009620666201009125507 crossref_primary_10_1200_GO_21_00089 crossref_primary_10_1038_s41571_020_0428_5 crossref_primary_10_1016_j_canep_2022_102195 crossref_primary_10_1093_jnci_djae334 crossref_primary_10_1002_humu_23804 crossref_primary_10_1186_s13058_023_01627_2 crossref_primary_10_3389_fonc_2020_606400 |
Cites_doi | 10.1056/NEJMsr1501341 10.1093/aje/kwq180 10.1002/cncr.29010 10.1002/bjs.1800790819 10.1007/s10549-010-1006-9 10.1136/jmg.2004.020446 10.1007/s13167-010-0037-y 10.1073/pnas.1007983107 10.1046/j.1365-2168.1999.01117.x 10.1016/j.annepidem.2013.06.008 10.1001/jamaoncol.2015.5495 10.3322/caac.21271 10.1126/science.7545954 10.1038/sj.bjc.6604275 10.1007/s10549-014-3195-0 10.1073/pnas.1115052108 10.1158/1055-9965.EPI-14-0675 10.1073/pnas.1415979111 10.1186/s13058-014-0474-y 10.1200/JCO.2014.57.1414 10.1126/science.1088759 10.1002/cncr.24200 10.1200/JCO.2008.19.6873 10.1007/s12687-017-0311-y 10.1186/1471-2164-12-184 10.1007/s10549-012-2136-z 10.1002/ijc.27326 10.1158/0008-5472.CAN-06-0503 10.1016/j.canep.2012.04.007 10.1158/1055-9965.EPI-11-0775 |
ContentType | Journal Article |
Copyright | 2018 by American Society of Clinical Oncology 2018 American Society of Clinical Oncology |
Copyright_xml | – notice: 2018 by American Society of Clinical Oncology 2018 American Society of Clinical Oncology |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
DOI | 10.1200/JCO.2018.78.3977 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
DocumentTitleAlternate | Inherited Breast Cancer in Nigerian Women |
EISSN | 1527-7755 |
EndPage | 2825 |
ExternalDocumentID | PMC6161833 30130155 10_1200_JCO_2018_78_3977 |
Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
GeographicLocations | Nigeria |
GeographicLocations_xml | – name: Nigeria |
GrantInformation_xml | – fundername: NCI NIH HHS grantid: K12 CA139160 – fundername: NCI NIH HHS grantid: U01 CA161032 |
GroupedDBID | --- .55 0R~ 18M 2WC 34G 39C 4.4 53G 5GY 5RE 8F7 AAQQT AARDX AAWTL AAYEP AAYOK AAYXX ABBLC ABJNI ABOCM ACGFO ACGFS ACGUR ADBBV AEGXH AENEX AIAGR ALMA_UNASSIGNED_HOLDINGS BAWUL BYPQX C45 CITATION CS3 DIK EBS EJD F5P F9R FBNNL FD8 GX1 H13 HZ~ IH2 K-O KQ8 L7B LSO MJL N9A O9- OK1 OVD OWW P2P QTD R1G RHI RLZ RUC SJN TEORI TR2 TWZ UDS VVN WH7 X7M YFH YQY CGR CUY CVF ECM EIF NPM 7X8 5PM |
ID | FETCH-LOGICAL-c462t-aa57412f8a9442138be6babeca0f279dbc9d36ae77643cb2e93088b7af1b3d873 |
ISSN | 0732-183X 1527-7755 |
IngestDate | Thu Aug 21 14:35:23 EDT 2025 Mon Jul 21 09:33:12 EDT 2025 Mon Jul 21 06:04:28 EDT 2025 Tue Jul 01 02:13:14 EDT 2025 Thu Apr 24 23:07:47 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 28 |
Language | English |
License | Licensed under the Creative Commons Attribution 4.0 License: http://creativecommons.org/licenses/by/4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c462t-aa57412f8a9442138be6babeca0f279dbc9d36ae77643cb2e93088b7af1b3d873 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 M.-C.K. and O.I.O. contributed equally to this work. Deceased. Y.Z. and T.W. contributed equally to this work. |
OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC6161833 |
PMID | 30130155 |
PQID | 2091822605 |
PQPubID | 23479 |
PageCount | 6 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_6161833 proquest_miscellaneous_2091822605 pubmed_primary_30130155 crossref_primary_10_1200_JCO_2018_78_3977 crossref_citationtrail_10_1200_JCO_2018_78_3977 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2018-10-01 |
PublicationDateYYYYMMDD | 2018-10-01 |
PublicationDate_xml | – month: 10 year: 2018 text: 2018-10-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Journal of clinical oncology |
PublicationTitleAlternate | J Clin Oncol |
PublicationYear | 2018 |
Publisher | American Society of Clinical Oncology |
Publisher_xml | – name: American Society of Clinical Oncology |
References | B20 B21 B22 B23 B25 B26 B27 B28 B29 B30 B31 B10 B11 B12 B13 B14 B15 B16 B17 B18 B19 B1 B2 B3 B4 B5 B6 B7 B8 B9 30130156 - J Clin Oncol. 2018 Oct 1;36(28):2817-2819. doi: 10.1200/JCO.2018.79.3307 |
References_xml | – ident: B10 doi: 10.1056/NEJMsr1501341 – ident: B12 doi: 10.1093/aje/kwq180 – ident: B21 doi: 10.1002/cncr.29010 – ident: B2 doi: 10.1002/bjs.1800790819 – ident: B6 doi: 10.1007/s10549-010-1006-9 – ident: B5 doi: 10.1136/jmg.2004.020446 – ident: B28 doi: 10.1007/s13167-010-0037-y – ident: B9 doi: 10.1073/pnas.1007983107 – ident: B1 doi: 10.1046/j.1365-2168.1999.01117.x – ident: B13 doi: 10.1016/j.annepidem.2013.06.008 – ident: B29 doi: 10.1001/jamaoncol.2015.5495 – ident: B30 doi: 10.3322/caac.21271 – ident: B18 doi: 10.1126/science.7545954 – ident: B11 doi: 10.1038/sj.bjc.6604275 – ident: B27 doi: 10.1007/s10549-014-3195-0 – ident: B15 doi: 10.1073/pnas.1115052108 – ident: B14 doi: 10.1158/1055-9965.EPI-14-0675 – ident: B23 doi: 10.1073/pnas.1415979111 – ident: B26 doi: 10.1186/s13058-014-0474-y – ident: B17 doi: 10.1200/JCO.2014.57.1414 – ident: B22 doi: 10.1126/science.1088759 – ident: B20 doi: 10.1002/cncr.24200 – ident: B3 doi: 10.1200/JCO.2008.19.6873 – ident: B31 doi: 10.1007/s12687-017-0311-y – ident: B16 doi: 10.1186/1471-2164-12-184 – ident: B8 doi: 10.1007/s10549-012-2136-z – ident: B7 doi: 10.1002/ijc.27326 – ident: B19 doi: 10.1158/0008-5472.CAN-06-0503 – ident: B4 doi: 10.1016/j.canep.2012.04.007 – ident: B25 doi: 10.1158/1055-9965.EPI-11-0775 – reference: 30130156 - J Clin Oncol. 2018 Oct 1;36(28):2817-2819. doi: 10.1200/JCO.2018.79.3307 |
SSID | ssj0014835 |
Score | 2.5485318 |
Snippet | Among Nigerian women, breast cancer is diagnosed at later stages, is more frequently triple-negative disease, and is far more frequently fatal than in Europe... |
SourceID | pubmedcentral proquest pubmed crossref |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 2820 |
SubjectTerms | Adult Breast Neoplasms - epidemiology Breast Neoplasms - genetics Female Genetic Predisposition to Disease Humans Middle Aged Mutation Nigeria - epidemiology ORIGINAL REPORTS |
Title | Inherited Breast Cancer in Nigerian Women |
URI | https://www.ncbi.nlm.nih.gov/pubmed/30130155 https://www.proquest.com/docview/2091822605 https://pubmed.ncbi.nlm.nih.gov/PMC6161833 |
Volume | 36 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3tT9QwGG8UE8IXI_h2IqYmhoTADtbu1u0jLhrQICQeCfpl6bpOLjl2hG0m-NfzPG23u4EY9Utzt_W6XX9Pn_7aPi-EvIvjYk_CTO2NFB95wG-VJ4HWQhEXOXyTXOM-5NGX8OA0-HQ2OmtzuDvvkjobql-_9Sv5H1ThGuCKXrL_gGzXKFyAz4AvlIAwlH-F8WGJ3nvIGd-jbXm9nSCGaGAOCP_ANyi3TYrKeyho5xY5K1Vve_37ubY64NvMJPlY2HavzD7M2P4bY7nTTKumzd_VgI65mNdPZCVzbQwGvk6mPydycZPBjzpzNZgjnGJkApi4Danbak4busRJiPPxdnowMi5udxU0s7mnk2O0qouGIhoiA12sCl18eWEA43iq6rtH9oNit7cekkdMAGlCNnz4uTs-CoBXujNpeODu7cetkOW2gT4dubPGuG0qu8A9xk_IY4cY3bcSsEoe6HKNLB85s4g1snliA5Bf79Dx3J-u2qGb9GQemvz6KdnqJIZaiaFWYuikpK3EUCMxz8jpxw_j5MBzyTI8FYSs9iQMscBnRSTjIGA-jzIdZhJGqNwrmIjzTMU5D6UWAjioypiOOUwwmZCFn_E8Evw5WSpnpX5JqFSFHyhYa8L1QEQSFmGaQbV8FIoCuMyA7LZ9lioXSR4TmkxTXFEyPB5NjlPs8FREKXb4gGx1v7i0UVT-UPdtC0MKqg7Pr2SpZ00FtWJYDeMCfEBeWFi61lo8B0T0AOsqYBj1_p1ycm7CqYeYM4LzV_e2uU5W5mPiNVmqrxq9AVS0zt4YsbsBO66Fyw |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Inherited+Breast+Cancer+in+Nigerian+Women&rft.jtitle=Journal+of+clinical+oncology&rft.au=Zheng%2C+Yonglan&rft.au=Walsh%2C+Tom&rft.au=Gulsuner%2C+Suleyman&rft.au=Casadei%2C+Silvia&rft.date=2018-10-01&rft.eissn=1527-7755&rft.volume=36&rft.issue=28&rft.spage=2820&rft_id=info:doi/10.1200%2FJCO.2018.78.3977&rft_id=info%3Apmid%2F30130155&rft.externalDocID=30130155 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0732-183X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0732-183X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0732-183X&client=summon |